{"id":34585,"date":"2016-12-20T11:13:05","date_gmt":"2016-12-20T09:13:05","guid":{"rendered":"http:\/\/www.ivi.uk\/?p=34585"},"modified":"2022-04-12T17:37:50","modified_gmt":"2022-04-12T15:37:50","slug":"ivi-and-the-oxford-university-hospitals-trust","status":"publish","type":"post","link":"https:\/\/www.ivi.uk\/blog\/ivi-and-the-oxford-university-hospitals-trust\/","title":{"rendered":"IVI and the Oxford University Hospitals Trust – working for the future fertility of young cancer survivors"},"content":{"rendered":"
Survival rates for childhood cancer are one of the great success stories of modern medicine: today 80% of children will survive. However, treatment using chemotherapy or radiotherapy will leave one in eight child cancer survivors infertile.<\/p>\n
As part of IVI\u2019s commitment to the evolution of and social responsibility in reproductive medicine, we have donated \u00a3250,000 to the Oxford University Hospitals NHS Foundation Trust to support and expand the storing of ovarian and testicular tissue from children before they receive cancer treatment.<\/p>\n
“We are delighted to receive this generous donation from IVI UK. At present tissue cryopreservation is not routinely funded by the NHS and so the donation will enable us to continue to offer this service to young people across England and Wales who are at high risk of infertility due to their cancer treatment.”<\/em> \nDr. Sheila Lane, Consultant Oncologist from the John Radcliffe Hospital.<\/small><\/p>\n
This clinical service provided by the NHS Trust and the Nuffield Department of Obstetrics & Gynaecology, University of Oxford, was founded in 2013 and was the first of its kind in England and Wales. It aims to give young people with cancer the option to have a family later in life.<\/p>\n
The IVI Foundation is the non-profit research and development division of IVI. The foundation will be involved in a collaborative research programme with the Nuffield Department of Obstetrics and Gynaecology to extend understanding of and treatment for infertility. The pioneering research includes projects on ovarian follicle development and sperm stem cell activation.<\/p>\n
Prof Antonio Pellicer, president of the IVI Group, said: “We hope that the donation will help to deliver this important service to young people with cancer. Alongside this, our Foundation will work with University Oxford on the basic science around restoring fertility to young people who undergo sterilising treatment for their cancer.”<\/em><\/p>\n